Trials / Withdrawn
WithdrawnNCT03832673
Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study
PECULIAR: An Open Label, Monocenter, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab and Epacadostat, Preceding Radical Cystectomy, for Patients With Muscle-invasive Bladder Cancer.
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
An open label, monocenter, single-arm, phase 2 study of neoadjuvant pembrolizumab and epacadostat, preceding radical cystectomy, for patients with muscle-invasive bladder cancer.
Detailed description
An open label, monocenter, single-arm, phase 2 study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles) |
| DRUG | Epacadostat | Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles) |
Timeline
- Start date
- 2019-05-22
- Primary completion
- 2019-05-22
- Completion
- 2019-05-22
- First posted
- 2019-02-06
- Last updated
- 2021-02-26
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT03832673. Inclusion in this directory is not an endorsement.